A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression
Public ClinicalTrials.gov record NCT02422186. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Subjects With Treatment-resistant Depression
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the efficacy and safety of switching elderly participants with treatment-resistant depression (TRD) from a prior antidepressant treatment (to which they have not responded) to either intranasal esketamine plus a new oral antidepressant or switching to a new oral antidepressant plus intranasal placebo.
Study identification
- NCT ID
- NCT02422186
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 139 participants
Conditions and interventions
Conditions
Interventions
- Esketamine Drug
- Placebo Drug
- Duloxetine (Oral Antidepressant) Drug
- Escitalopram (Oral Antidepressant) Drug
- Sertraline (Oral Antidepressant) Drug
- Venlafaxine Extended Release (XR) (New Antidepressant) Drug
Drug
Eligibility (public fields only)
- Age range
- 65 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 20, 2015 (Actual)
- Primary completion
- Aug 10, 2017 (Actual)
- Completion
- Aug 10, 2017 (Actual)
- Last update posted
- Apr 29, 2025
2015 – 2017
United States locations
- U.S. sites
- 15
- U.S. states
- 13
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | San Diego | California | — | — |
| Not listed | New Haven | Connecticut | — | — |
| Not listed | Miami | Florida | — | — |
| Not listed | Marietta | Georgia | — | — |
| Not listed | Iowa City | Iowa | — | — |
| Not listed | Baltimore | Maryland | — | — |
| Not listed | Watertown | Massachusetts | — | — |
| Not listed | New York | New York | — | — |
| Not listed | Staten Island | New York | — | — |
| Not listed | Cincinnati | Ohio | — | — |
| Not listed | Allentown | Pennsylvania | — | — |
| Not listed | Dallas | Texas | — | — |
| Not listed | Wichita Falls | Texas | — | — |
| Not listed | Charlottesville | Virginia | — | — |
| Not listed | Richland | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 54 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02422186, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 29, 2025 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02422186 live on ClinicalTrials.gov.